Roche Pharmaceutical Development and Sales Overview

Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication Metastatic and/or recurrent PD-L1+ cervical cancer (CC) Neoadjuvant and adjuvant NSCLC 1L non-squamous NSCLC Phase/study # of patients Design Phase II SKYSCRAPER-04 N=172 " ARM A: Tiragolumab plus Tecentriq ARM B: Tecentriq " Roche Phase II SKYSCRAPER-05 N=82 ARM A: (PD-L1 high) neoadjuvant tiragolumab plus Tecentriq followed by adjuvant tiragolumab plus Tecentriq or adjuvant chemotherapy ARM B: (PD-L1 all-comers) neoadjuvant tiragolumab plus Tecentriq plus chemo followed by adjuvant tiragolumab plus Tecentriq Pathologic complete response, major pathological response and safety ■ FPI Q2 2021 " " Phase III SKYSCRAPER-06 N=540 ARM A: Tiragolumab plus Tecentriq plus pemetrexed plus chemo followed by maintenance tiragolumab plus Tecentriq plus pemetrexed ARM B: Placebo plus pembrolizumab plus pemetrexed plus chemo followed by maintenance placebo plus pembrolizumab plus pemetrexed Objective response rate, progression-free survival and overall survival FPI Q4 2020 Objective response rate " Primary endpoint FPI Q2 2020 Status CT Identifier NCT04300647 NSCLC-Non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1 NCT04832854 NCT04619797 106 Oncology

View entire presentation